SLU-PP-332 Research Information
Pan-ERR Agonist & Exercise Mimetic
For Metabolic & Mitochondrial Research
⚠️ Important: This information is for educational and research purposes only. Always consult with a qualified healthcare professional before use.
📑 Contents
🔬 What is SLU-PP-332?
SLU-PP-332 is a synthetic pan-agonist for Estrogen-Related Receptors (ERRα, ERRβ, and ERRγ) that acts as a powerful "exercise mimetic" [citation:2][citation:3][citation:6]. It is a small molecule (C18H14N2O2, MW 290.32) that selectively activates the ERR receptors, which are master regulators of cellular energy metabolism, without affecting estrogen receptors ERα or ERβ [citation:1][citation:5][citation:6].
SLU-PP-332 has garnered significant attention for its ability to enhance mitochondrial function, increase oxidative muscle fibers, and improve exercise endurance in preclinical studies [citation:2][citation:8]. It is available in pen and freeze-dried vial formulations for research purposes.
⚡ How SLU-PP-332 Works
SLU-PP-332 works through a targeted mechanism that mimics the molecular effects of endurance exercise [citation:3][citation:6][citation:8]:
ERR Activation
Binds and activates ERRα (EC50: 98 nM), ERRβ (230 nM), and ERRγ (430 nM) [citation:1][citation:2][citation:3]
PGC-1α Pathway
Activates PGC-1α, the master regulator of mitochondrial biogenesis [citation:6][citation:8]
Exercise Mimetic
Induces an acute aerobic exercise genetic program without physical activity [citation:2][citation:3][citation:8]
SLU-PP-332 enhances mitochondrial respiration in skeletal muscle cells and increases oxidative fibers, improving exercise endurance in an ERRα-dependent manner [citation:2][citation:3][citation:8]. ERRγ is the main mediator of ERR agonism-induced transcriptional regulation and cardioprotection [citation:4].
📋 Research Applications
Exercise Mimetic
Studied for its ability to replicate the benefits of endurance training at a molecular level [citation:3][citation:8]
Metabolic Disorders
Potential for studying obesity, diabetes, and metabolic dysfunction [citation:1][citation:8]
Heart Failure
Significantly improved ejection fraction and survival in pressure overload-induced HF models [citation:4]
Aging & Mitochondria
Investigating mitochondrial health and age-related metabolic decline [citation:6][citation:8]
📊 Clinical Studies
Exercise Endurance (ACS Chem Biol, 2023)
- SLU-PP-332 (50 mg/kg, b.i.d., i.p.) increased oxidative fibers in skeletal muscle and improved exercise endurance in C57BL/6J mice [citation:2]
- Induced an acute aerobic exercise genetic program in skeletal muscles [citation:2][citation:3]
- Increased Ddit4 and Slc25a25 gene expression in an ERRα-dependent manner [citation:3]
Heart Failure (Circulation, 2024)
- Both SLU-PP-332 and SLU-PP-915 significantly improved ejection fraction, ameliorated fibrosis, and increased survival in pressure overload-induced HF models [citation:4]
- ERRγ is the main mediator of ERR agonism-induced transcriptional regulation and cardioprotection [citation:4]
- ERR agonists maintain oxidative metabolism, conferring cardiac protection [citation:4]
Metabolic & Aging Models
- In diet-induced obese mice, SLU-PP-332 decreased fat mass and improved glucose metabolism [citation:3][citation:6]
- In aging kidney models, it improved mitochondrial function and inhibited inflammatory markers like IL-6 and TNF-α [citation:6]
- Reduced fat deposition by approximately 12-20% without suppressing food intake [citation:6]
💉 Interactive Dosing Guide
Select your vial size and dose to see the corresponding volume, clicks, dosing frequency, and how many doses per vial:
🖊️ Step 1: Select Your Vial Size
💊 Step 2: Select Your Dose
Vial Size
5mg Vial
Selected Dose
0.1 mg
Doses per Vial
50 doses
Pen Clicks
6 clicks
Volume
0.06 mL
Protocol Level
Level 1 (Starting)
Recommended Schedule
Daily - Loading Phase
⚠️ Do not change your dose unless advised by a qualified professional.
📋 Protocol Level Summary
Based on research protocols: 0.1-2 mg daily [citation:2][citation:3]. In animal studies, 50 mg/kg b.i.d. was used, with human-equivalent doses not yet established [citation:8].
| Protocol Level | Target Dose | Frequency | Pen Clicks | Volume (mL) | Who It\'s For |
|---|---|---|---|---|---|
| Level 1 (Starting) | 0.1 mg | Daily | 6 clicks | 0.06 mL | New users, first 2 weeks |
| Level 2 (Standard) | 0.25 mg | Daily | 15 clicks | 0.15 mL | After 2 weeks, maintenance |
| Level 3 (Advanced) | 0.5 mg | Daily | 30 clicks | 0.30 mL | If more response needed |
| Level 4 (Maximum) | 1-2 mg | Daily | 60-120 clicks | 0.60-1.20 mL | Experienced users only |
⚠️ Do not change your dose unless advised by a qualified professional.
💉 Vial Users (Insulin Syringe)
Add 3mL of bacteriostatic water to your freeze-dried vial and mix gently. After reconstitution, use the table below to draw your dose:
Vial Size
5mg vial with 3mL bac water
| Dose | Frequency | Units on Syringe | Volume (mL) | Protocol Level |
|---|
⚠️ Always use a new sterile needle and syringe for each injection.
⚠️ Safety & Precautions
Short-term preclinical safety data suggest SLU-PP-332 is tolerated at effective doses in rodents, with no severe adverse events reported [citation:6][citation:8]. However, comprehensive toxicology studies and human safety data are currently unavailable [citation:6][citation:8].
Important safety considerations:
- No human safety data exists for SLU-PP-332 [citation:8]
- Long-term effects of chronic ERR receptor activation are unknown [citation:8]
- Potential risk of off-target effects from powerful master regulators [citation:8]
- Not approved for human use; strictly a research compound [citation:1][citation:2][citation:6]
Do not use if you:
- Are allergic to SLU-PP-332 or any ingredients
- Are pregnant or breastfeeding
- Have pre-existing medical conditions (consult a healthcare professional first)
⚠️ Warning: SLU-PP-332 is an experimental research compound with no human safety data. If you experience severe allergic reactions, difficulty breathing, or signs of anaphylaxis, seek immediate medical help.
📚 References
- Billon C, et al. Synthetic ERRα/β/γ Agonist Induces an ERRα-Dependent Acute Aerobic Exercise Response and Enhances Exercise Capacity. ACS Chem Biol. 2023;18(4):756-771. [citation:2][citation:5]
- Xu W, Billon C, Li H, et al. Novel Pan-ERR Agonists Ameliorate Heart Failure Through Enhancing Cardiac Fatty Acid Metabolism and Mitochondrial Function. Circulation. 2024;149(3):227-244. [citation:4]
- Validating ERRα-Dependent Effects of Slu-PP-332: A Comparative Guide Using Knockout Mice. BenchChem. December 2025. [citation:3]
- SLU-PP-332 Peptide: An Experimental Exercise-Mimetic Targeting Mitochondrial Aging. AMD Alliance. 2026. [citation:8]
This information is for educational and research purposes only. Always consult with a qualified healthcare professional.
Last updated: July 2026